Jan 27 (Reuters) - The U.S. ​Centers for ‌Medicare & Medicaid Services ‌on Tuesday named a new group of ⁠branded ‌drugs from ...

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

This biotech has candidates in late-stage clinical development.

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

The company got some bad news to start 2026.

Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold in 2026. On January 20, Eli Lilly received FDA ...

Both companies may succeed in this industry.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...